Medivation (MDVN) overall volatility elevated at 170 into Phase 3 results

Medivation (Nasdaq: MDVN) closed at $18.73 into the upcoming MDV3100's Phase III trial in post-chemotherapy prostate cancer patients. Overall option implied volatility of 170 is above its six-month average of 90 according to Track Data, suggesting larger price movement.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BJ's Wholesale Club (BJ) call put ratio 1.3 calls to 1 put into quarter results
• Oracle (ORCL) October 175 calls active as share price up 3.6%
• SpaceX (SPCX) call put ratio 1.5 calls to 1 put as share price up 1.4%